Skip to main content

Table 1 Baseline demographic, anamnestiс, clinical and laboratory characteristics of JIA severity in patients enrolled in the study

From: Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial

Parameter ETA + MTX (n = 35) Placebo + MTX (n = 33) p
Demographic characteristics
 Sex: 0.471
  female, n (%) 22 (64.71%) 25 (75.76%)
  male, n (%) 12 (35.29%) 8 (24.24%)
Age at enrolment, years; median (IQR range) 9.8 (5.82–12.94) 6.62 (4.1–13.26) 0.11
Disease duration (starting from the onset symptoms) to baseline years; median (IQR range) 0.81 (0.29–1.68) 0.74 (0.32–3.48) 0.632
Age of onset of specific complaints years; median (IQR range) 7.2 (4.38–10.82) 4.7 (2.4–9.44) 0.032
Age at diagnosis years; median (IQR range) 9.16 (5.4–12.05) 4.86 (2.49–11.37) 0.035
Disease duration until diagnosis, years 2.5 (1–9) 3 (2–16) 0.38
JIA category
 Seronegative Polyarthritis, n (%) 21 (60%) 16 (48%) 0.47
 Seropositive Polyarthritis, n (%) 1 (2.9%) 0 1.0
 Extended Oligoarthritis, n (%) 8 (23%) 12 (36%) 0.29
 Polyarticular enthesitis associated arthritis, n (%) 5 (14.3%) 3 (9%) 0.71
 Unclassified polyarticular JIA, n (%) 0 2 (6%) 0.23
Prior treatment
 Conventional NSAIDs, n (%) 31 (88.57%) 27 (81.82%) 0.507
 COX-2 inhibitors, n (%) 11 (32.35%) 13 (39.39%) 0.729
 Sulfasalazine, n (%) 6 (17.14%) 9 (27.27%) 0.475
 Leflunomide, n (%) 1 (2.86%) 0 (0%) > 0.999
 Oral GCs, n (%) 1 (2.86%) 2 (6.06%) 0.608
 Other GCs, n (%) 11 (31.43%) 8 (24.24%) 0.697
Clinical and laboratory characteristics
 Swollen joint count, median (IQR range) 6 (4–9) 4 (2–7) 0.018
 Tender joint count, median (IQR range) 6 (4.5–12.5) 6 (4–12) 0.349
 Number of joints with LOM, median (IQR range) 6 (4.5–10.5) 6 (3–14) 0.521
 Number of active joints, median (IQR range) 7 (6–11.5) 7 (4–12) 0.191
 Haemoglobin, median (IQR range) 12 (11.45–12.8) 12 (11.4–12.5) 0.726
 ESR, median (IQR range) 12 (2–20) 12 (8–23) 0.301
 CRP, median (IQR range) 3.5 (1–13.45) 0.7 (0–9) 0.003
 JADAS-71, median (IQR range) 24 (18–34) 19 (17–24.3) 0.025
 CHAQ, median (IQR range) 1.5 (0.75–1.75) 1 (0.5–1.5) 0.057
 Physician’s assessment of disease activity using VAS, median (IQR range) 8 (6–9) 6 (5–7) 0.014
 Patient’s assessment of well-being using VAS 8 (5–9) 7 (5–8) 0.114
 Patient’s assessment of disease activity using VAS, median (IQR range) 7.5 (5–8) 7 (5–8) 0.353
  1. P values are based on the Mann-Whitney U-test (for continuous data) and on Pearson’s χ2 test (for categorical data)